Wynzora
intended to target inflammatory skin lesions to alleviate psoriasis symptoms.
Strengths: 0.05/0.005%
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Corticosteroid; Vitamin D analogue
- Pharmacological class
Glucocorticoids; Vitamin D3 derivative
- Minor side effects
pruritus; skin irritation
- Moderate side effects
folliculitis; skin atrophy; pigmentary changes
- Dosage forms
Cream
- Administration route
Cutaneous use
- Patient summary
intended to target inflammatory skin lesions to alleviate psoriasis symptoms.
- Prescription status
POM
- Manufacturer
LEO Pharma
- Onset Time
1–2 weeks
- Duration
up to 8 weeks
- Storage instructions
Store below 25°C.
- Age restrictions
Not for children under 18 years.
Contraindications
calcium metabolism disturbance; viral skin infections; tuberculosis of the skin; hypersensitivity to components
Precautions and warnings
avoid application on the face; limit total weekly dosage; avoid excessive exposure to sunlight
Serious side effects
hypercalcaemia — requires immediate medical attention; cushing's syndrome — requires immediate medical attention
Mechanism of action
Combines a potent corticosteroid for anti-inflammatory effects and a vitamin D analogue to regulate skin cell growth and reduce hyperproliferation.
Pregnancy and breastfeeding
Pregnancy: Use with caution only if benefits outweigh risks. Breastfeeding: Avoid application to the breasts.
Wynzora
intended to target inflammatory skin lesions to alleviate psoriasis symptoms.
Editorial Notes
- Active ingredient(s): Betamethasone, Calcipotriol
- Listed indication(s): Plaque Psoriasis
Available option
- 2 tubes - 0.05/0.005 %1558-0-05-0-005-pct-18097